Department of Pathology, Josephine Nefkens Institute, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Virchows Arch. 2012 Aug;461(2):149-56. doi: 10.1007/s00428-012-1277-0. Epub 2012 Jul 10.
Urothelial cell carcinoma (UCC) with musculus detrusor (MD) invasion is treated by cystectomy. Subsequent pathologic evaluation of cystectomies does not reveal MD invasion (<pT2) in a subgroup of patients. Our objective was to identify features at diagnostic transurethral resection (TUR) predicting down-staging (<pT2) at cystectomy. Patients with pathologically confirmed MD invasion at TUR followed by cystectomy for UCC without (neo-) adjuvant therapy were included (N = 106). Slides of both TUR and cystectomy specimens were reviewed, and survival analyses were performed. In total, 27/106 (26 %) tumors were down-staged at cystectomy, of which 13 (12 %) had no residual tumor (pT0). There was no significant difference in age, gender, time interval between TUR and operation, number of slides sampled, and presence of TUR scar between down-staged (<pT2) and pT2 UCC. At review of TUR specimens (N = 52) with UCC initially diagnosed as pT2, MD invasion was not confirmed in eight cases (15 %). One case showed extensive histiocytic reaction misinterpreted as UCC; in four cases, muscularis mucosae had been considered MD, and in three cases, desmoplastic reaction mimicked MD. No histologic parameter at TUR was significantly associated with down-staging at cystectomy. Overall and disease-specific survival was not statistically different in down-staged and pT2 UCC. In conclusion, down-staging of UCC (<pT2) at cystectomy occurred in 26 %. At review of diagnostic TURs, MD invasion was not confirmed in 15 %. No clinical or pathologic parameter was predictive for down-staging at cystectomy. There was no difference in survival between down-staged and pT2-staged UCC.
尿路上皮细胞癌(UCC)合并逼尿肌侵犯(MD)采用膀胱切除术治疗。在部分患者中,膀胱切除术后的后续病理评估未发现 MD 侵犯(<pT2)。我们的目的是确定在经尿道切除术(TUR)诊断时的特征,这些特征可预测在膀胱切除术后降级(<pT2)。纳入了在 TUR 时病理证实有 MD 侵犯,随后因 UCC 而未接受(新)辅助治疗而行膀胱切除术的患者(N = 106)。对 TUR 和膀胱切除标本的切片进行了复查,并进行了生存分析。总共,在 106 例患者中,有 27 例(26%)肿瘤在膀胱切除术后降级,其中 13 例(12%)无残留肿瘤(pT0)。在 TUR 后降期(<pT2)和 pT2UCC 中,年龄、性别、TUR 和手术之间的时间间隔、取样切片数量以及 TUR 疤痕的存在均无显著差异。在对最初诊断为 pT2 的 UCC 进行 TUR 标本(N = 52)复查时,有 8 例(15%)未确认 MD 侵犯。1 例病例表现为广泛的组织细胞反应,被误诊为 UCC;在 4 例病例中,黏膜肌被认为是 MD,在 3 例病例中,纤维组织反应模仿 MD。在 TUR 中没有任何组织学参数与膀胱切除术后降期显著相关。在降期和 pT2UCC 中,总生存率和疾病特异性生存率无统计学差异。总之,在膀胱切除术后有 26%的 UCC 降级(<pT2)。在对诊断性 TUR 进行复查时,有 15%未确认 MD 侵犯。没有临床或病理参数可预测在膀胱切除术后降期。降期和 pT2 分期的 UCC 之间的生存率没有差异。